DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
Key Highlights
- ➤FDA proposes interim access policy for compounding using certain peptides
- ➤Corexa Pharmacy plans peptide prescriptions once FDA interim policy takes effect
- ➤Corexa Distribution licensed in all 50 states targets peptide supply for pharmacies
- ➤Corexa Tech & Hub expects growth routing peptide prescriptions through Health Lives Here
- ➤U.S. compounding pharmacy market projected to exceed $34 billion annually by 2035
Expert Statements
Gerald Commissiong, Interim Co-CEO of DataMEDS
“We were very pleased to see FDA begin to act on PCAC's recommendations so quickly”
Gerald Commissiong, Interim Co-CEO of DataMEDS
“Corexa Health has three separate pharmacy-focused divisions to address key needs within the independent pharmacy space as it relates to the tremendous potential opportunities that peptides provide to improve human health and provide greater choice for consumers, in addition to the business opportunity for pharmacies.”
Gerald Commissiong, Interim Co-CEO of DataMEDS
“Corexa Pharmacy is a 503A compounding pharmacy and intends to begin to fill prescriptions for peptides eligible for compounding under FDA's interim policy once it goes into effect. We have initiated a thorough review of potential providers of suitable drug substance and intend to formalize contracts with appropriate partners in the coming weeks in preparation for what we anticipate will be significant demand. Because we expect the peptide market to be predominantly cash pay initially, there appears to be a significant opportunity for Corexa Pharmacy to benefit with reduced exposure to PBM clawbacks and other insurance-related reimbursement challenges. Our Corexa Distribution division is licensed in all 50 states and is positioned to serve as a channel for independent pharmacies to be able to access compliant sources of peptide drug substance so that they can meet the demand of their local communities. Our 40,000 square foot warehouse in Lakeland, Florida is able to purchase products on a wholesale basis for sale to pharmacies, as well as serve as a third-party logistics (3PL) provider for peptide manufacturers seeking a strategically located warehouse solution that can deliver products to pharmacies in all 50 states. We intend to work closely with prospective peptide manufacturing partners, as well as our network of 6,500+ independent pharmacies to help improve peptide access for patients throughout the country, especially in rural areas.”
Gerald Commissiong, Interim Co-CEO of DataMEDS
“Our Corexa Tech & Hub division presents potentially the most compelling opportunity for growth and value creation, especially given the recent launch of the Health Lives Here mobile application.”
Gerald Commissiong, Interim Co-CEO of DataMEDS
“Due to the nature of the hub receiving the prescriptions from physicians and routing them to Corexa Pharmacy or a local pharmacy of the patient's choosing, the hub is positioned to see significant growth as physicians increasingly become the conduit for consumers to procure peptides eligible for compounding. Our Electronic Benefits Verification (EBV) offering will be able to keep patients, providers and pharmacies up-to-date on any changes in insurance coverage for peptides.”
TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx(™) and smart contracts platform PharmacyChain(™), today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled "Interim Access Policy for Compounding Using Certain Peptides." The new proposed policy comes less than three months following the recommendation from FDA's Pharmacy Compounding Advisory Committee (PCAC) to loosen restrictions on the use of six peptides. The U.S. compounding pharmacy market is expected to grow from $18 billion in 2025 to over $34 billion annually by 2035, according to Precedence Research.
Concurrently, the Company's pharmacy-focused subsidiary Corexa Health provided a roadmap for how it intends to capitalize on the improving peptides regulatory landscape.
Get started
Create a free account to read the full story.